Spotlight on HDL-raising therapies: insights from the torcetrapib trials

Nature Clinical Practice. Cardiovascular Medicine
Anatol KontushM J Chapman

Abstract

Subnormal levels of HDL cholesterol constitute a major cardiovascular risk factor. Inhibitors of cholesteryl ester transfer protein (CETP) are presently the most potent HDL-raising agents. Torcetrapib was the first CETP inhibitor to enter a large-scale, prospective, placebo-controlled interventional trial, which was prematurely terminated in December 2006 because of excess cardiovascular and noncardiovascular mortality in the active treatment group. Therapy with torcetrapib was associated with considerable increases in aldosterone level and blood pressure and changes in serum electrolytes indicative of mineralocorticoid excess. These findings indicate that torcetrapib has off-target toxic effects unrelated to HDL raising that involve the activation of mineralocorticoid receptors by aldosterone and result in the induction of hypertension. In contrast with torcetrapib, other CETP inhibitors such as JTT-705 and MK-825 do not increase blood pressure in humans, an observation which discounts a class effect. The available data do not, however, exclude potential adverse effects of CETP inhibition such as the generation of HDL particles that have deficient biological activities and a deleterious impact on reverse cholesterol transport ...Continue Reading

References

Sep 1, 1979·Circulation·D B Zilversmit
May 1, 1994·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·M GuérinM J Chapman
Oct 16, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·J S CohnJ Davignon
Jun 25, 2005·Circulation Research·Gary F Lewis, Daniel J Rader
Feb 7, 2006·Journal of the American College of Cardiology·Philip J Barter, John J P Kastelein
Mar 1, 2006·Nature Clinical Practice. Cardiovascular Medicine·Anatol Kontush, M John Chapman
Apr 1, 2006·Arteriosclerosis, Thrombosis, and Vascular Biology·John S MillarDaniel J Rader
Jul 13, 2006·Current Opinion in Lipidology·Mohamad NavabAlan M Fogelman
Feb 27, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Laurent Yvan-CharvetAlan R Tall
Mar 3, 2007·The Journal of Clinical Investigation·Tomas VaisarJay W Heinecke
Mar 28, 2007·The New England Journal of Medicine·Steven E NissenUNKNOWN ILLUSTRATE Investigators
Mar 28, 2007·The New England Journal of Medicine·John J P KasteleinUNKNOWN RADIANCE 1 Investigators
Mar 30, 2007·Clinical Pharmacology and Therapeutics·E LaiK Gottesdiener
Jun 9, 2007·Current Opinion in Cardiology·Göran Walldius, Ingmar Jungner
Jul 11, 2007·Current Opinion in Lipidology·Benjamin J AnsellAlan M Fogelman
Aug 21, 2007·JAMA : the Journal of the American Medical Association·Erik IngelssonRamachandran S Vasan
Aug 21, 2007·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Stefan P J DullensRonald P Mensink
Aug 22, 2007·Circulation·Joost Daemen, Patrick W Serruys
Sep 28, 2007·The New England Journal of Medicine·Philip BarterUNKNOWN Treating to New Targets Investigators
Oct 24, 2007·Arteriosclerosis, Thrombosis, and Vascular Biology·Maryse GuerinM John Chapman
Nov 7, 2007·The New England Journal of Medicine·Philip J BarterUNKNOWN ILLUMINATE Investigators
Nov 7, 2007·The New England Journal of Medicine·Daniel J Rader
Dec 6, 2007·The American Journal of Cardiology·Vaijinath S Kamanna, Moti L Kashyap
Dec 6, 2007·The American Journal of Cardiology·Prediman K Shah
Jan 5, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Scott M Grundy
Feb 12, 2008·Journal of the American College of Cardiology·Jacques Genest
Mar 28, 2008·Current Diabetes Reports·Anatol Kontush, M John Chapman

❮ Previous
Next ❯

Citations

Apr 29, 2010·Current Atherosclerosis Reports·Anatol Kontush, M John Chapman
Jun 9, 2009·Cardiovascular Research·Karin R SipidoVirginija Dambrauskaite
Nov 18, 2011·Pharmacological Reviews·João Pedro de MagalhãesChintan Vora
Mar 28, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·W Sean DavidsonAnatol Kontush
Feb 15, 2011·The Journal of Clinical Investigation·Martina LukasovaStefan Offermanns
Jun 18, 2010·Cellular and Molecular Life Sciences : CMLS·Olaf WeberMichael-Friedrich Böttcher
Jan 1, 2009·Expert Opinion on Drug Discovery·Keith Suckling
Feb 18, 2011·Expert Opinion on Emerging Drugs·Matilda FlorentinMoses S Elisaf
Oct 8, 2013·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Pablo Corral, Laura Schreier
Feb 16, 2010·Pharmacology & Therapeutics·M John ChapmanPhilippe Giral
Nov 11, 2009·Advanced Drug Delivery Reviews·David P CormodeZahi A Fayad
Jun 2, 2010·Journal of Atherosclerosis and Thrombosis·Shizuya YamashitaMakoto Nishida
Mar 27, 2010·Journal of the American College of Cardiology·Pradeep NatarajanChristopher P Cannon
Dec 7, 2011·Bioorganic & Medicinal Chemistry Letters·Zhijian LuPeter J Sinclair
Nov 6, 2012·Clinica Chimica Acta; International Journal of Clinical Chemistry·Alejandro GugliucciSatoshi Kimura
Jul 1, 2016·Journal of Molecular Endocrinology·Aurelie Nguyen Dinh CatRhian M Touyz
May 25, 2011·AJR. American Journal of Roentgenology·Brian F ChapinChristopher G Wood
Apr 21, 2009·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·H F G FreitasA J Mansur
Dec 9, 2010·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·P M CazitaE C R Quintão
Jul 25, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Anatol Kontush, M John Chapman
Jun 5, 2013·Indian Journal of Surgical Oncology·Ginil Kumar PooleriAppu Thomas
Nov 5, 2011·Current Urology Reports·Javier González
Jan 27, 2015·The Journal of Pharmacology and Experimental Therapeutics·Francisco J RiosRhian M Touyz
Nov 23, 2011·Current Urology Reports·Paul L Crispen, Michael L Blute

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Risk Prediction

Cardiovascular risk prediction models based on classical risk factors identified in epidemiological studies are useful in primary prevention of cardiovascular disease in individuals. Here is the latest research.